Current Treatment Options in Neurology

Current Treatment Options in Neurology is published by Springer US and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Epilepsy research and treatment, Parkinson's Disease Mechanisms and Treatments and Acute Ischemic Stroke Management, together about 19.5% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)

This journal aims to review the most important, recently published treatment option advances in the field of neurology. By presenting clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to the treatment of neurologic conditions.We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as epilepsy, headache, neurologic ophthalmology and otology, neuromuscular disorders, psychiatric manifestations of neurologic disease, and sleep disorders. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known neurologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Classification of EvidenceNext to reference numbers in the body of the paper, authors have supplied an evidence classification number so that readers can evaluate the type of evidence used to support the idea presented.Example: “Alcohol may help essential tremor, but addiction is a possibility [2, Class III].”This indicates that the reader should refer to reference number 2 on the reference list at the end of the article, which is considered Class III evidence by the author.The standard definitions of classification of evidence are as follows:Class I: Evidence provided by one or more well-designed, randomized, controlled clinical trials, including overviews (meta-analyses) of such trials.Class II: Evidence provided by a well-designed, matched-group cohort study or by a randomized, controlled clinical trial lacking in one design criterion.Class III: Evidence provided by other controlled trials such as those with natural history controls or patients serving as their own controls, with independent outcome assessments. Class IV: Evidence provided by expert opinion, case series, case reports, or uncontrolled studies.These classifications are based on those used by the American Academy of Neurology. For more detailed guidance on assigning a classification, see Appendix 9 in the AAN Clinical Practice Guideline Process Manual, 2004 Edition, available at http://www.aan.com/globals/axon/assets/2535.pdf

From the journal's Aims & Scope

Research area (LetPub): CLINICAL NEUROLOGY

Editor-in-chief Amos D. KorczynPublisher website

Editorial board by country: 1 in mainland China (about 7%); most named United States 8, Germany 2, Israel 2, Mainland China 1, United Kingdom 1 (15 members with a country) Editorial board ↗Publisher website · 2026-09-29

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

EmbaseCurrent ContentsPublisher website

Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

1.3LetPub · 2026-09-13

Impact factor (publisher) 2025

1.3Publisher website · 2026-09-29

5-year impact factor (publisher) 2025

1.8Publisher website · 2026-09-29

CiteScore 2026-06

3.2LetPub · 2026-09-13

SJR 2026-06

0.48LetPub · 2026-09-13

SNIP 2026-06

0.66LetPub · 2026-09-13

h-index

38LetPub · 2026-09-13

h-index

77OpenAlex · 2026-10-01

i10-index

855OpenAlex · 2026-10-01

2-year mean citedness

1.93OpenAlex · 2026-10-01

Self-citation rate

0%LetPub · 2026-09-13

Share of gold OA articles

21.24%LetPub · 2026-09-13

Volume

Articles per year

43LetPub · 2026-09-13

Downloads per year (publisher) 2025

263,300Publisher website · 2026-09-29

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Submission to first decision

4 daysPublisher website · 2026-09-29

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Springer US

Country or region

US

Language

English

Frequency

Bimonthly

Founded

1999

ISSN

1092-8480

Electronic ISSN

1534-3138

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Author guidelines ↗LetPub
• Special issues ↗Publisher website